Arcus Biosciences Announces Anti-TIGIT Program Update
Company Announcements

Arcus Biosciences Announces Anti-TIGIT Program Update

Arcus Biosciences Inc (RCUS) has released an update.

The Company released a press statement on January 29, 2024, providing updates on its anti-TIGIT clinical development program.

For further insights into RCUS stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.

Related Articles
TipRanks Auto-Generated NewsdeskArcus Biosciences Reports Q3 2024 Results
TheFlyArcus Biosciences reports Q3 EPS ($1.00), consensus ($1.06)
TheFlyArcus Biosciences announces results from Part 1 of ARC-10 trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App